MOVR 2.0
Help Shape the Future of Neuromuscular Research
Join MOVR 2.0
The Muscular Dystrophy Association (MDA) is launching the next phase of its national patient data platform — and you’re invited to be part of it.
What is MOVR 2.0?
MOVR 2.0 is a secure, research-driven data platform designed to reflect what matters most to people living with neuromuscular disease. By sharing your medical history, you’ll help advance research, improve care, and accelerate the development of new treatments.
MOVR 2.0 Is Just the Beginning The Muscular Dystrophy Association (MDA) is launching a six-month early testing phase of MOVR 2.0, a new data platform designed to support individuals living with spinal muscular atrophy (SMA). For now, this phase is focused exclusively on the SMA community so we can ensure the platform meets your needs and works seamlessly.
Once the pilot is concluded, we plan to expand MOVR 2.0 to include additional neuromuscular diseases—making it available to even more patients and families across the community.
This is where we need your input! By enrolling and sharing feedback on your experience, you’ll help shape a meaningful and impactful platform for future participants.
You’ll also gain access to tools that help you better understand your own health journey.
Why Join MOVR 2.0?
- Visualize Your Health
Track trends and changes in your condition with easy-to-understand dashboards.
- Stay Informed
Receive updates from MDA’s research team, including opportunities to participate in new studies or clinical trials.
- Drive Progress
Your real-world experience helps researchers and clinicians better understand neuromuscular diseases and what’s needed next.
This pilot was developed with input from individuals living with neuromuscular disease. Your voice makes it stronger, smarter, and more impactful.
Who Can Join This Study?
During the six-month pilot phase, we will be accepting a limited number of families to join MOVR 2.0 who live in the U.S. and are diagnosed with spinal muscular atrophy (SMA)—regardless of age or gender.
MOVR 2.0 is aiming to open enrollment towards the end of 2025 with a limited number of spots available. After the pilot wraps up, MDA plans to expand participation to include more neuromuscular disease diagnosis, so even more individuals can get involved.
